Previous 10 | Next 10 |
Continues to be launch ready for PALFORZIA TM EU and Swiss regulatory reviews for PALFORZIA remain on schedule Uninterrupted drug supply for all ongoing clinical trials $371.6 million cash, cash equivalents and investments on-hand and implementing numerous ca...
COVID-19 Is Distracting Investors from an Amazing Market Opportunity While the world remains hyper-focused on COVID-19 as the biggest healthcare challenge of the past century, it is perhaps easy to overlook progress being made to treat more mundane (yet far more durable) medical problems. ...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Monday, May 11, 2020, at 4:30 p.m. ET to discuss its financial results for t...
Aimmune Therapeutics ( AIMT ) was a stock I followed and invested in and also recommended to my subscribers before the approval. The stock did double over a period of 6 months, however, there were some jittery moments right before Palforzia’s (AR101) approval with unscheduled delays and...
On March 16, Aimmune Therapeutics (NASDAQ: AIMT) announced that the first patients in the U.S. had begun treatment with its recently approved immunotherapy for peanut allergies, Palforzia. On the same day, investors learned that the U.S. Food and Drug Administration (FDA) had questions ...
For parents, having a child with peanut allergies come into accidental contact with the protein, via unlabeled foods at a potluck event, birthday party, or school lunch can be devastating. The results range in severity, from minor skin reactions to life-threatening anaphylaxis. It's an...
The Food and Drug Administration (FDA) made numerous drug approval decisions in the first quarter. These binary events can cause stock prices to skyrocket or plummet depending on the outcome. Here we explore four companies that successfully attained FDA approval. It marked the first drug ever...
Introduction At the end of 2019 I wrote an article highlighting the reasons why I felt DBV Technologies (NASDAQ: DBVT ) was substantially undervalued. At the time DBVT was trading for around $9, subsequently climbed to $13.49 by mid-January, and then nosedived to a low of $2.02. The s...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the 19 th Annual Needham Virtual Healthcare Conf...
Aimmune (AIMT) has been on my 2019 watch list, but the stock's premium price prevented me from committing to a buy. Now, the recent sell-off has AIMT near the top of my shopping list. The company is in the process of launching their first FDA-approved product, Palforzia, for the mitigation of ...
News, Short Squeeze, Breakout and More Instantly...
Aimmune Therapeutics Inc. Company Name:
AIMT Stock Symbol:
NASDAQ Market:
— Majority of Patients Experienced Low Rates of Adverse Events, Which Declined in Frequency and Severity with Continued Treatment — — Systemic Allergic Reactions and Epinephrine Use Were Low and Decreased Over Time — Aimmune Therapeutics, ...
-- Peanut Allergy is One of the Most Common Food Allergies in Europe -- -- Up to 1.6% of European Children Live with Potentially Life-Threatening Peanut Allergy -- Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Com...
VEVEY, Switzerland , Sept. 14, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a cash tender offer to purchase all of the outstanding shares of common s...